Enfusion (NYSE:ENFN) Issues Earnings Results

Enfusion (NYSE:ENFN - Get Free Report) posted its earnings results on Monday. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02), Zacks reports. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The business had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million.

Enfusion Stock Performance

Shares of NYSE:ENFN traded down $0.16 during midday trading on Thursday, hitting $11.29. The company's stock had a trading volume of 1,097,137 shares, compared to its average volume of 1,169,438. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 282.20, a PEG ratio of 1.85 and a beta of 0.95. The stock's 50 day simple moving average is $10.96 and its 200 day simple moving average is $9.86. Enfusion has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Analysts Set New Price Targets

A number of research analysts have recently commented on ENFN shares. William Blair reissued a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Piper Sandler increased their price target on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus lifted their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Enfusion presently has a consensus rating of "Hold" and a consensus price target of $11.13.

Remove Ads

Insider Activity

In related news, COO Neal Pawar sold 2,769 shares of Enfusion stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the sale, the chief operating officer now directly owns 1,231,627 shares of the company's stock, valued at $14,139,077.96. This trade represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now directly owns 270,503 shares in the company, valued at approximately $2,870,036.83. This trade represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,022 shares of company stock valued at $492,706. 36.44% of the stock is owned by insiders.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.